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Introduction: Several studies in developed countries such as the USA have 
reported low serum or plasma vitamin A levels in adults with HIV disease. 
Limited data suggests that HIV-infected adults from developing countries show 
even lower vitamin A levels. Factors that contribute to a low vitamin A status 
include a poor intake, malabsorption and repeated episodes of infections 
resulting in a decreased hepatic mobilisation of vitamin A during the acute phase 
response, an accelerated utilisation of vitamin A or increased urinary losses of 
vitamin A. Aim: To determine the vitamin A status of HIV-infected adults without 
major active opportunistic infections with WHO clinical stages 1 to 4 HIV-
infection. Methods: One hundred and thirty two HIV-positive patients were 
included in a cross-sectional study at the outpatient clinic at Groote Schuur 
Hospital. Exclusion criteria included current use of multivitamin or vitamin A 
supplements, pregnancy, pyrexia (> 38 ° C ) and patients who had received TB 
treatment for less than 12 weeks. We obtained data on demographic 
characteristics, weight and height, CD4 lymphocyte levels, CD4:CD8 ratio, full 
blood count and plasma levels of retinal, retinal-binding protein, zinc and CRP. 
Results: The sample consisted of 51, 48 and 33 patients with WHO Stage 1/2, 3 
and 4 HIV-infection, respectively. The proportion of patients with borderline 
vitamin A levels ( < 30 µg/dl) for male and female subjects increased linearly 
across clinical stage categories. Thirty nine percent (20/51) of patients with early 
disease, 48% (23/48) with Stage 3 HIV-disease and 79% (26/33) of patients with 
AIDS showed a borderline vitamin A status (p < 0.001 ). Plasma retinal status 
was associated with CD4 lymphocyte levels (r=0.27; 95% Cl: 0.1-0.43) and the 
CD4:CD8 ratio (r=0.33; 95% Cl: 0.1 ;0.42). Only one subject demonstrated CRP 
levels > 100 mg/I. Seventy seven percent (39/51) of patients with early disease 
had CRP levels < 1 O mg/I, compared to 52% (25/48) and 58% (19/33) of patients 
with stage 3 and 4 HIV disease. CRP levels were divided according to 3 
categories: < 10 mg/I, 10-40 mg/I and > 40 mg/I. The median retinal level of 
patients with CRP levels> 40 mg/I (n=7) was 16.8 µg/1 versus 27.3 µg/1 and 30.2 
µg/1 in the other two categories (p < 0.05). A similar relationship between CRP 
and plasma zinc levels was observed, although not significant (p < 0.1 ). 
Multivariate analysis revealed that a borderline retinal status was independently 
associated with a 3-fold increase (95%CI: 2-5.6) in the risk of having stage 4 
disease or AIDS after adjusting for CD4 lymphocyte count or the CD4:CD8 ratio, 
haemoglobin, plasma zinc and body weight. Conclusions: Patients with 
advanced disease are more likely to have a borderline vitamin A status in the 
absence of opportunistic infections. The majority of patients with symptomatic 
disease had mildly raised CRP levels, possibly reflecting HIV-viral activity. CRP 
levels were associated with low retinal levels only in a small number of subjects, 
possibly indicating the presence of underlying infection, despite the clinical 
review of our data. Although our data indicates an independent relationship 
between retinal levels and advanced disease, the cross-sectional design 
precludes causal inferences about this association. 
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1 Introduction 
Factors affecting survival in patients with the Acquired Immunodeficiency 
Syndrome (AIDS) was recently reviewed by Mocroft et al. (1 ). In their response 
to the review, Baum et al. noted the author's omission of the role of micronutrient 
status in disease progression and survival. Baum et al concluded: "Although 
nutrient deficiencies are unlikely to be the principal cause of immune 
dysregulation in HIV-1 disease, these data indicate that they may be important 
cofactors and play a contributory role to influence the survival of HIV/AIDS 
patients" (2). 
A number of specific micronutrient deficiencies in plasma or serum including 
vitamins A, B6, B12, E, copper, zinc and selenium have been reported in Human 
Immunodeficiency virus (HIV) infection and in AIDS (3,4,5,6,7). 
Deficiencies of these micronutrients, as well as more global forms of protein-energy 
depletion, clearly influence various components of cell-mediated immunity such as 
T-lymphocyte proliferation, lymphocyte responses to mitogens and natural killer 
activity, that are also affected by HIV-infection (8). 
Among the micronutrients, vitamin A and its metabolites are particularly important 
for T and B lymphocyte function, cellular differentiation and haematopoiesis 
(9, 10, 11 ). Vitamin A deficiency in HIV-disease has been associated with lower 
CD4 lymphocyte counts and with an increased mortality in HIV-disease 
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(12,13,14). Factors that may result in a deficient vitamin A status in HIV 
infection include a decreased dietary intake, malabsorption due to diarrhoea and 
repeated episodes of infections resulting in a decreased mobilisation of hepatic 
reserves of vitamin A during the acute phase response, increased utilisation of 
vitamin A by target tissues or increased urinary losses of vitamin A during 
episodes of intercurrent infections (11, 15, 16). A wide range of reported vitamin A 
deficiency prevalence in HIV disease may reflect the inclusion of individuals at 
various stages of disease, those who have active opportunistic infections versus 
those who do not, or those taking vitamin supplements versus those who do not 
(6, 12, 13, 14, 17, 18). 
In conclusion, several studies have looked at the vitamin A status in adults with HIV 
disease in developed countries such as the USA. Little published data exists for 
developing countries. The prevalence of vitamin A deficiency in the HIV-positive 
population and in adult HIV-positive patients attending health facilities in South 
Africa is unknown. The ideal study design to investigate risk factors such as a low 
serum vitamin A status with the development of AIDS as endpoint or outcome 
measure, would be a prospective cohort study. Due to time constraints this was not 
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2 Aim and Objectives 
2.1 Aim 
To determine the serum vitamin A status amongst HIV-seropositive patients and its 
relationship with clinical stage and controlling for the effects of immune function and 
the acute phase response. 
2.2 Objectives 
The objectives of this study are: 
(i) to compare the proportion of patients without major active opportunistic 
infections with low plasma retinal levels within WHO clinical stages 1 to 4 
HIV-infection, 
(ii) to determine the relationship between plasma retinal and CD4 lymphocyte 
levels and the CD4:CD8 lymphocyte ratio 
(iii) to determine the relationship between plasma retinal and the acute phase 
response as reflected by plasma levels of C-reactive protein, zinc and 
retinal-binding protein (RBP) ; 
(iv) to determine whether plasma retinal is independently associated with clinical 
stage 4 (AIDS) adjusting for potential confounding, intermediate and effect 
modifying variables. Variables that could be included are body mass index 
(BMI), Total lymphocyte count (TLC), C04 lymphocyte levels, Haemoglobin, 
Haematocrit, CRP, RBP and zinc and 
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(v) to examine potential predictor variables of low plasma retinal levels which 
are clinically relevant such as WHO clinical stage, BMI, TLC, C04 
lymphocyte levels, Haemoglobin, Haematocrit , CRP and zinc. 
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3 Literature Review 
3.1 Vitamin A 
Vitamin A has been described as the "anti-infective vitamin" since the 1920s (1 ). 
Today it is recognised as an essential micronutrient for immunity, cellular 
differentiation, maintenance of epithelial surfaces, haematopoiesis, growth, 
reproduction and vision (2,3). 
Clinical vitamin A deficiency is characterised by clinical indicators such as night 
blindness and xeropthalmia. Subclinical deficiency is associated with reduced 
biochemical indicators such as serum retinal and liver retinal levels in the absence 
of clinical manifestations. The level of depletion at which physiological functions 
begin to be impaired is not entirely clear. What is known is that the integrity of 
epithelial barriers and the immune system are compromised before the visual 
system is affected (4). 
3.2 Vitamin A, immunity and infection 
Experimental studies indicate that vitamin A deficiency-induced immune 
abnormalities include atrophy of the thymus and spleen, reduced lymphocyte 
counts and lymphocyte mitogenic responses and impairment of macrophage 
function. Antibody affinity, production and response are also impaired. Vitamin A 
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deficiency also results in decreased cellular turnover, stratification of epithelial 
cells and ultimately squamous metaplasia, keratinisation and desquamation of cells 
(2). 
The evidence that vitamin A is essential for immunity in humans has been 
summarised by Semba et al. based upon epidemiological observations and clinical 
trials as follows: 
(i) Infectious diseases are associated with vitamin A deficiency; 
(ii) Vitamin A deficiency is associated with increased morbidity and mortality 
from infectious diseases; 
(iii) Specific immune alterations take place during vitamin A deficiency in 
humans; 
(iv) Vitamin A and its metabolites are essential to T-and B-cell growth and 
function; 
(v) Vitamin A supplementation enhances immunity in humans and 
(vi) Vitamin A supplementation reduces morbidity and mortality from infectious 
diseases in children (3). 
It should be noted that the effect of vitamin A deficiency on the immune system can 
be obscured by changes in immune responsiveness induced by accompanying 
protein-energy malnutrition (PEM). Scrimshaw et al. were the first to suggest an 
overall hypothesis of synergistic interaction between malnutrition and infection, 
largely based upon investigations among malnourished children in developing 
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countries (5). Human and experimental studies have confirmed that protein-
energy malnutrition (PEM) and deficiencies of iron, vitamin B6 and zinc are all 
associated with a depressed cell mediated immune response (6,7). 
In a study on vitamin-A-deficient children in which the confounding effect of PEM 
was reduced by the exclusion of acutely malnourished children according to 
anthropometric criteria, the vitamin-A-deficient children had lower CD4 lymphocyte 
levels and a decreased CD4: CDs lymphocyte ratio, compared to non-deficient 
children. High dose vitamin A supplementation reversed these abnormalities (8). 
In a meta-analysis of 20 controlled trials of vitamin A supplementation for the 
prevention of death or morbidity from infectious disease, it was concluded that high 
dose vit. A supplementation reduced morbidity and mortality from infectious 
diseases such as measles, pneumonia and diarrhoea in children in developing 
countries. Results suggested a reduction in all cause mortality of 30% (95% Cl: 
21 %; 38%) (9). 
The biological mechanisms by which vitamin A affect morbidity and mortality are 
unclear. Two main types of mechanisms have been considered namely, the effects 
of vitamin A on epithelial integrity and on the immune system. 
3.3 Vitamin A, infection and the acute-phase response 
During infections serum retinal levels may drop due to decreased food intake, 
decreased absorption, decreased mobilisation of hepatic reserves of retinal during 
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the acute-phase response, an increased utilisation of retinal by target tissues and 
increased urinary losses of vitamin A (3, 10, 11 ). The inflammatory response to 
infection or the acute-phase response has been summarised by Koj & Gordon 
(1985) as "an early and unspecific highly complex reaction of the animal organism 
to a variety of injuries, such as bacterial or parasitic infection, mechanical or thermal 
trauma, malignant growth or ischaemic necrosis" (12). The systemic acute phase 
responses include fever, alterations in vascular permeability, leucocytosis, 
increased plasma copper, decreased plasma iron and zinc, increased 
glucocorticoid concentrations and changes in hepatic plasma proteins. Bacterial 
infection frequently gives a stronger stimulus to the acute-phase response than viral 
or parasitic infection. The acute-phase response still occurs in severe malnutrition, 
but is reduced (13). 
"Positive acute-phase proteins" are those proteins whose serum concentrations 
increase during the acute phase response which include C-reactive protein (CRP), 
serum amyloid A protein (SAA), a1-antitrypsin, aracid glycoprotein, fibrinogen and 
caeroluplasmin. In contrast, "negative acute-phase proteins" are those proteins 
whose serum concentrations decrease which include albumin, pre-albumin, retinal-
binding protein (RBP) and transferrin. The functions of the acute-phase proteins 
are not fully understood but include immunoregulation, removal of foreign material 
from the body, inhibition of proteases, binding of minerals and promotion of blood 
clotting (13,14). 
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During the acute phase response plasma zinc and iron levels decrease due to 
hepatic sequestration, whereas copper levels increase due to an increase in 
caeruloplasmin. Serum retinol levels have been negatively associated with 
markers of the acute-phase response such as elevated CRP levels. in adults 
undergoing orthopaedic surgery. and in Zimbabwean schoolchildren with 
schistosomiasis (15, 16). Decrease retinol levels may be caused by a reduced 
mobilisation of RBP from the liver due to hypozincaemia, since RBP is a zinc-
dependent protein. RBP may also be lowered because of increased vascular 
permeability during the systemic acute-phase response (2, 13, 14). 
Although lowered retinol levels during the acute-phase response have been 
attributed to a reduced mobilisation of retinol from the liver, Campos et al. found 
that a single episode of chicken pox in children was associated with the depletion of 
liver vitamin A stores, suggesting that vitamin A requirements are increased during 
infection (10). 
The effects of vitamin A supplementation on the acute phase response in Ghanaian 
children was investigated in a randomised, controlled trial. Acute-phase responses 
to fever and cough were not affected by supplementation. Children with vomiting or 
diarrhoea who received vitamin A supplementation demonstrated higher levels of 
acute-phase proteins (17). 
The precise effect of the acute-phase response on the metabolism of vitamin A is 
not clear, but it is well documented that infections result in lowered serum retinol 
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levels and hepatic vitamin A stores. In view of the close relationship between the 
availability of vitamin A and immune effector cell function, low serum levels of 
vitamin A during infection may therefore have detrimental effects on the immune 
response (3). 
3.4 Vitamin A status in HIV infection/AIDS 
Factors that may result in a deficient vitamin A status in HIV infection include a 
poor nutritional intake, diarrhoeal disease or malabsorption, and repeated episodes 
of infection. 
Studies in the USA have reported deficient serum vitamin A levels in HIV-1 
seropositive individuals and in AIDS patients. 
Beach et al. studied 100 asymptomatic HIV-positive homosexual men and 42 age-
matched seronegative controls and found that the prevalence of vitamin A 
deficiency at baseline (defined as serum retinol levels less than 30 µg/dl) was 11 % 
(18). Baum et al. using a similar cohort, found that the mean baseline serum retinol 
level of the HIV-positive men (43 ± 11 µg/dl) was significantly lower than the 
seronegative controls (51 ± 13 µg/dl), despite a very high intake of vitamin A in the 
HIV-positive men (19). 
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In a randomly selected sub-sample of 179 seropositive and seronegative 
individuals from a cohort of 2000 intravenous drug users, the prevalence of vitamin 
A deficiency in the seropositive group, was 15% (20). 
In a study consisting of only 25 HIV-positive outpatients (8 symptomatic patients 
and 15 asymptomatic patients), patients with AIDS not taking a daily multivitamin 
supplement containing modest amounts of vitamin A, demonstrated the lowest 
serum retinal levels in the sample (21 ). 
In a cross-sectional study amongst hospitalised AIDS patients not receiving 
vitamin A supplementation, 22% of patients had severe vitamin A deficiency 
(defined as serum retinal levels less than 20 µg/dl). Two subgroups were 
described with lower mean serum retinal levels compared to the mean serum 
retinal level of the sample, namely patients with diarrhoea and those with non-
Pneumocystis carinii pneumonia. Karter et al. commented that 27% of patients 
with an adequate dietary vitamin A intake during the preceding 4 weeks before 
hospitalisation, still demonstrated deficient serum retinal levels (22). 
Maternal vitamin A deficiency has been reported in 58% and 32% of seropositive 
pregnant women in Africa and in the USA, respectively. These high prevalences 
in pregnant seropositive women could be partly explained by the increased 
requirements for vitamin A by the developing foetus. Both studies suggested a 
four-to-five fold increased risk of mother-to-child transmission of HIV in those 
who were vitamin A deficient compared to those who were not deficient. The 
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increased risk of transmission may result from altered mucosa! immunity, 
altered pathology of the reproductive tract, abnormalities of the placenta or 
increased foetal susceptibility to infection (23,24). 
Thus, a wide range of reported vitamin A deficiency prevalence in HIV disease 
could reflect the inclusion of individuals at various stages of disease, those with or 
without active opportunistic infections, as well as the use of multivitamin or vitamin 
A supplements. 
3.5 Vitamin A and the progression of HIV disease 
The relatively high prevalence of micro-nutrient abnormalities in early HIV-infection 
has inspired interest in determining whether abnormalities such as vitamin A 
deficiency in particular, contribute to the progression of HIV disease to AIDS or to 
the survival of AIDS patients. 
In a prospective cohort study of 281 HIV-positive men, Tang et al. investigated the 
association between the daily intake of micronutrients from food and supplements 
in early HIV-infection with the rate of progression to the development of AIDS. A 
Cox proportional hazards model was adjusted for energy intake, age, presence of 
HIV-symptoms, CD4 lymphocyte count at baseline and the use of antiretrovirals and 
Pneumocystis carinii pneumonia prophylaxis. Smoking and alcohol intake were not 
included in the final model since neither were related to disease progression and 
therefore not considered as confounders. They showed that the relationship 
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between the dietary intake of vitamin A and the progression to AIDS was U-
shaped, with the middle two quartiles of vitamin A intake being associated with 
significantly slower progression to AIDS (25). 
In another prospective study in 296 HIV-seropositive men, Abrams et al. could not 
demonstrate any association between the dietary intake of 11 micronutrients at 
baseline and progression to AIDS after adjusting for energy intake, age, baseline 
CD4 lymphocyte count, HIV-symptoms and smoking. A higher vitamin A intake was 
associated with higher CD4 lymphocyte levels at baseline after controlling for age, 
smoking, symptoms and total energy intake (26). It should be noted that both these 
studies related the risk of progression to AIDS to dietary intake at baseline and the 
influence of subsequent dietary change was not evaluated. 
Vitamin A deficiency (defined as serum retinol levels less than 1.05 µmol) predicted 
mortality in a sample of 179 seropositive and seronegative individuals from a cohort 
of intravenous drug users, after adjusting for CD4 counts of less than 200 cells/ml 
and Hepatitis B surface antigen (RR=6.3; 95%Cl:2.1; 18.6). Current use and 
duration of IV drug use, antiretroviral treatment, alcohol consumption and history of 
diarrhoea were not significantly related to mortality using a proportional hazards 
model (20). A nested case control study within the same cohort on 50 AIDS 
patients who had died compared to 235 controls who had survived, showed that a 
4-fold increase in the risk of death if vitamin A deficiency was recorded during their 
last study visit before death, after adjusting for CD4 counts and body weight at their 
last visit (27). 
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Baum et al. examined the relationship between micronutrient status at baseline 
and over time with immunological markers of disease progression in a prospective 
study. They showed that the development of vitamin A deficiency was associated 
with a decline in CD4 levels, while normalisation of serum vitamin A levels was 
associated with higher CD4 cell counts (28). 
Finally, another prospective study with 311 seroprevalent men was unable to show 
any association between serum vitamin A levels and disease progression, CD4 cell 
decline or mortality. The absence of any significant finding was attributed to the 
vitamin A status of the cohort being in the normal to high range (median retinol level 
= 69.9 µg/dl) (Tang 1997). 
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4 Methods 
4.1 Study design 
A cross-sectional study. 
4.2 Time frame 
October 1995 to October 1996. 
4.3 Study population 
Male and female HIV-antibody-positive patients with heterosexually acquired 
HIV-infection, attending the Groote Schuur Hospital HIV-outpatient clinic in whom 
routine blood tests were requested by the attending physician. HIV-seropositivity 
was determined according to WHO guidelines by means of three positive 
enzyme-linked immunosorbent assays (ELISAs) that uses different antigens and 
have differing test principles (1 ). 
Exclusion criteria: 
less than 18 years of age 
active major opportunistic infection (requiring hospitalisation) 
pyrexia > 38.0 °Cat enrolment 
patients who had received TB treatment for less than 12 weeks 
clinical diagnosis of liver cirrhosis 
anti-retroviral therapy e.g. AZT 
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any multivitamin or vitamin A supplements during the preceding 6 months 
pregnancy (patients were asked re. the date of their last menstrual period) 
prisoners 
4.4 Sample size 
One study in the USA reported the proportion of AIDS patients with low serum 
retinal levels who were not receiving vitamin supplements as 22% (2). In the 
current study, the proportion of patients with WHO Clinical Stage IV (AIDS) with low 
serum vitamin A levels was estimated at 40%. 
Clinic attendance records showed that attendance was evenly distributed amongst 
patients within clinical stages 1 and 2, clinical stage 3 and 4 HIV-infection. The Chi-
square test for trend was used to derive different scenarios, assuming that the 
proportion of patients with a low serum vitamin A status differed between the clinical 
strata by greater or equal to 10%. 
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Binomial distribution: n = (100/0)2 x 1.962 x p(1-p) 
p p p D N 2 X trend 
Clinical Clinical Clinical 
Stage Stage 3 Stage 4 
1+2 
0.2 0.3 0.4 0.075 143 4.3 
(p=0.0381) 
0.2 0.3 0.4 0.05 322 10.43 
(p=0.0012) 
A sample size of 322 subjects was not attainable within the specified time period, 
since this is much larger than the annual patient attendance at the Groote Schuur 
Hospital Outpatient Clinic. Due to methodological reasons it was decided not to 
include other outpatient clinics in the present study. The required sample size at a 
precision level of 7.5% is 143 subjects. 
4.5 Measurements 
4.5.1 Clinical Stage 
Patients were classified according to the WHO Staging system for the 
classification of HIV disease. The WHO Staging system consists of both a 
clinical and a laboratory axis. The clinical axis is represented by HIV-associated 
clinical conditions that are considered to have prognostic significance and are 
subdivided into one of four clinical stages: stage I: asymptomatic infection/ 
persistent generalized lymphadenopathy; stage II: early disease; stage Ill: 
intermediate disease and stage IV: late disease (Appendix 1) WHO Stage IV is 
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equivalent to the 1987 Centres for Disease Control (CDC) definition of AIDS 
(3,4). The clinical stage of each patient was assessed by a physician according 
to the WHO Clinical Staging system and recorded on a standard data sheet. The 
initial AIDS-defining illness was recorded for Stage IV patients. 
It has been demonstrated that patients with WHO stage I and II HIV-disease 
display similar survival curves (5). Therefore, during data analysis patients with 
Stage I and II HIV- infection were grouped together, representing early HIV-
disease. 
4.5.2 Retinol 
Serum levels of vitamin A is the most commonly used biochemical measure of 
vitamin A status, but serum levels become predictive of an individual's status 
only when body reserves have been critically depleted or overfilled. It should be 
noted that the Relative Dose Response Test (RDR) show greater validity as a 
marker of marginal liver vitamin A stores than a single serum sample. The RDR 
requires a fasting blood sample followed by a small dose of vitamin A and 
another blood sample to be taken after 5 hours (6,7). This method was not 
feasible in this study since patients only attend the clinic during the afternoon. 
The WHO has recommended that the following criteria should be used for the 
interpretation of serum vitamin A levels: Deficient: < 10 µg/dl (< 0.35 µmol/1); 
Low: 10 - 19 ~tgl/dl (0.35 - 0.69 µmol/1); Normal: 20 - 50 ~tg/dl (0.7 - 1.75 ~tmol/1) 
24 
and High: > 50 µg/dl (> 1.75 µmol/1) (8). However, US population-based data 
suggest that values in the range of 20-30 µg/dl (0.7 - 1.05 µmol/1) may be 
inadequate in particular for post-adolescent age groups (6,9). Therefore, in this 
study blood retinal status was categorised as follows: 
(i) borderline retinal levels defined as levels less than 30 µg/dl (1.05 µmol/1); 
(ii) low retinal levels defined as levels less than 20 µg/dl (0.7µmol/l) and 
(iii) deficient retinal levels defined as levels less than 10 µg/dl (0.35 µmol/1). 
Pregnant patients were excluded from this study because serum retinal levels 
decrease during pregnancy even among well-nourished women and are 
therefore not a good reflection of vitamin A status (10). 
Venous blood samples were taken in heparinised tubes covered with tin foil to 
protect from light. Samples were refrigerated immediately until centrifugation 
was possible, after which samples were frozen at -20 °C. It has been shown that 
under these storage conditions, vitamin A is stable for several years (11 ). 
Plasma retinal was determined using the fluorometric method (12). Each batch of 
samples was calibrated against two retinal standards and one plasma control 
using the spectrophotofluorometer. The interassay coefficient of variation (CV) 
was 7%. The intra-assay CV was previously determined at 7.55%. 
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4.5.3 Possible confounding, intermediate or effect modifying variables 
4.5.3.1 Body weight, height and Body Mass Index (BMI) 
The Body Mass Index (BMI) or Quetelet index is defined as body weight divided 
by the square of the height (BMI= kg/m2). A BMI of less than 18.5 had been 
suggested as the cut off point for identifying adults who are suffering from chronic 
energy malnutrition in developing countries (13). 
The degree of body wasting, and specifically lean body mass wasting has been 
associated with mortality in AIDS patients (14; 15). Wasting (> 10% loss of usual 
weight) is included in the WHO staging system for HIV disease and has been 
shown to be a risk factor for mortality in AIDS patients (15). However, it has 
been shown that a low BMI is a better predictor of mortality in HIV-disease than 
wasting. It has been suggested that the weight loss criterion which is included in 
the WHO Staging system should be replaced with the BMI criterion because this 
allows clinicians and researchers to determine the body weight status at a single 
point in time, rather on relying on weight change over an unspecified interval (16). 
Subjects were asked to remove heavy clothing and shoes. A balance scale 
which was calibrated at regular intervals was used to measure body weight to the 
first decimal point. A standard measuring stick was used to measure height to 
the nearest 0.5 cm. The BMI was calculated for each subject. 
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4.5.3.2 Total Lymphocyte Count (TLC), CD4 Count and CD4/CDa ratio 
T-lymphocyte levels may be measured by the absolute number or percentage of 
CD4 T-cells, the number of CD8 T-cells or the ratio of C04 to CDa T-cells. 
A significant increase in CD4 lymphocyte counts has been demonstrated after 3 
months of TB therapy in seropositive patients with pulmonary Tuberculosis (PTB) 
(17). This potential confounding effect of TB on the CD4 count was controlled in 
this study by restricting the inclusion criteria to patients who had received TB 
treatment for at least 12 weeks. 
The total white cell count was used as an input value for the determination of 
TLC, CD4 and CDa T-lymphocyte levels by flow cytometry. Variability in C04 and 
CD8 T-lymphocyte levels between and within laboratories occur due to 
techniques used in cell labeling, type of antibody used, type of machine, 
expertise of the operators and standardization of machine alignment, number of 
cells counted and normal variations in cell populations (18). To avoid inter-
laboratory variation one laboratory was used (Department of Clinical 
Immunology, Department of Medicine, UCT). The intra-assay CV has previously 
been determined at 4%. 
C04 lymphocyte counts do show diurnal variation and therefore blood samples 
should ideally be taken in the morning. This was not feasible in this study. Blood 
samples were taken in heparinised tubes. Samples were stored at room 
temperature and analysed within 24 hours after collection. 
The reference ranges for TLC, CD4 levels and the C04:CDa lymphocyte ratio 
are depicted in Table 4.1. 
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Table 4.1 Reference ranges for TLC, CD4 levels and the CD4:CDa 
lymphocyte ratio 
Total lymphocyte count 
C04 T-cells 
C04:CD8 ratio 
4.5.3.3 Haemoglobin and Haematocrit 
Reference range 
1500 - 4000 X 106/1 
500 - 2010 X 106/1 
> 1.5 
Haematopoiesis is reflected by haemoglobin and haematocrit levels. Full blood 
counts was performed on all blood specimens with the use of a blood counter 
(Technicon H2 systems). The reference ranges for haemoglobin and 
haematocrit are given in Table 4.2 below. 
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Table 4.2 Reference ranges for haemoglobin and haematocrit for 
males and females 
Haemoglobin (g/dl) Haematocrit (%) 
Males 13.3 - 17.3 0.37 - 0.53 
Females 11.6-15.6 0.32 - 0.48 
4.5.3.4 C-reactive protein (CRP), plasma zinc and retinal-binding protein 
(RBP) 
C-reactive protein (CRP) is described as a marker of the acute phase response, in 
that following an acute stimulus the plasma CRP concentration rises within 6 hours, 
reaching a peak at 50 hours. Similarly, on cessation of a stimulus, the plasma CRP 
concentration declines in an exponential manner in view of its short life of 5 to 7 
hours (19). During the acute phase response serum zinc levels decrease due to 
hepatic sequestration of zinc and may influence serum retinal via its effect on retinal 
binding protein (RBP) which is a zinc-dependent protein (20,21 ). 
The puncture site was cleaned with trace-element free alcohol to avoid 
contamination of the blood sample with zinc. Venous blood was placed in plastic 
tubes with plastic tops, since vacutainers with rubber stoppers contain zinc. 
Samples were refrigerated immediately until centrifugation was possible. 
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Plasma CRP and RBP levels were determined using a Behring nephelometer. 
This method was standardised against an international reference preparation for 
plasma proteins (22). The normal CRP concentration in adults may be regarded 
as less than 1 Omg/1, although a few healthy individuals may have a slightly higher 
value (19). The adult reference range for RBP is 3.5-9 mg/di (23). 
Plasma zinc levels show diurnal and postprandial variation and therefore fasting 
blood samples should ideally be taken in the morning (23). This was not feasible 
in this study. Plasma zinc concentration was determined using atomic absorption 
spectrophotometry. Each batch of samples was calibrated against five standards 
which were 20 µg/dl, 50 µg/dl, 100 µg/dl, 150 µg/dl and 200 µg/dl. The intra-
assay coefficient of variation (CV) was 5-9%. The interassay CV was previously 
determined at 6%. The reference range for zinc in plasma is 70-150 µg/dl (23). 
4.6 Pilot study 
A pilot study was initiated during October 1995 amongst 10 male and female 
patients attending the GSH HIV Outpatient Clinic. Patient folders were screened 
to identify patients in whom routine blood tests were requested by the attending 
physician and according to the inclusion criteria. A 10ml venous blood sample 
was taken in a heparinised tube with a plastic screw top, in addition to the routine 
blood tests requested for each patient. This blood sample was protected from 
light with tin foil and immediately refrigerated. All samples were centrifuged 
within 12 hours after collection and put into aliquots before it was stored at -20 °. 
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Consent was taken from all subjects and a short questionnaire for the 
collection of demographic variables such as age and proxies for socio-economic 
status such as educational level, current employment, type of housing, and the 
availability of electricity or a refrigerator (24,25). 
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5 Statistical Analysis 
Data was computerised and analysed on Epi-info, version 6 and SAS Statistical 
package, version 6.03. The normality of all the continuous variables was assessed 
by examining the stem-and leaf and the box plots, the normal probability plots and 
by the Shapiro-Wilk test for normality. 
The relationship between clinical stage and plasma retinal levels was analysed with 
plasma retinal as a categorical and as a continuous variable. The proportion of 
patients with borderline plasma retinal levels (<30 µg/dl) and low plasma retinal 
levels (<20 µg/dl) within clinical stages 1 and 2, clinical stage 3 and clinical stage 4 
was compared, using the Chi-square test for trend. The median plasma retinal 
levels within clinical stages 1 and 2, clinical stage 3 and clinical stage 4 was 
compared using the Kruskal-Wallis test. 
The relationship between plasma retinal levels and absolute CD4 lymphocyte cell 
count and the CD4:CD8 ratio was assessed by examining the linear association, 
using the Spearman correlation coefficient. The median plasma retinal levels was 
compared in patients with an absolute C04 lymphocyte cell count of less than and 
above 200 cells/µI and in patients with a CD4:CD8 ratio of less than and above 
0.15 with the Wilcoxon rank-sum test. 
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C-reactive protein (CRP) was categorised as follows: < 10 mg/I, 10-40 mg/I and 
40 mg/I. The relationships of plasma CRP levels with retinal, retinal-binding protein 
and zinc were assessed by the comparison of the median plasma levels of these 
variables within the three categories of CRP, using the Kruskal-Wallis test. 
Correlations between all the continuous variables such as plasma retinal, body 
weight, BMI, CD4 lymphocytes, TLC, haemoglobin, haematocrit, RBP,CRP and zinc 
was performed using the Spearman correlation coefficient. The presence of 
collinearity (r ~ 0.8) was examined in order to prevent the inclusion of strongly 
correlated variables into the multivariate model. 
Multivariate logistic regression was used to determine whether plasma retinal is 
independently associated with clinical stage 4 as outcome variable. Potential 
confounding variables such as body weight, BMI, absolute CD4 lymphocyte cell 
count and CD4:CD8 ratio, haemoglobin, haematocrit, CRP and serum zinc levels 
were entered into a multivariate model. Variables showing collinearity were entered 
independently into the model. Interaction terms were evaluated. The same 
procedure was followed to examine a logistic regression model with a borderline 
plasma retinal as outcome variable.. Models were assessed in terms of model fit, 
statistical and clinical significance. Residual analysis was performed on the final 
multivariate models to determine the effect of individual observations on the 
parameter estimates of each model and to identify observations that were not well 
fitted by each of the models. 
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7 Results 
A total of 247 patients with heterosexually acquired HIV-disease attended the HIV-
positive outpatient clinic at Groote Schuur Hospital during the period October 1995 
to December 1996 (excluding January 1996). Blood tests were not requested in 38 
patients. The following patients were excluded according to the exclusion criteria: 
less than 18 years (n=1), the presence of active opportunistic infection at the time 
of the clinic visit (n=9), patients who received TB therapy for less than 3 months 
(n=30), clinical diagnosis of liver disease (n=3), multivitamin supplements at the 
time or during the preceding 6 months (n=17), pregnancy (n=9), prisoners (n=1) 
and problems with venous access (n=2). One patient refused to participate in the 
study. 
Data was collected on 136 subjects. All subjects had a temperature less than 38°C 
recorded at the time of the study. One blood sample was haemolysed making it 
unsuitable for analyses. Clinical review of the data further excluded 1 patient with a 
Cryptococcal infection who had received treatment for less than 3 weeks and 2 
patients in whom M. tuberculosis was diagnosed shortly after they were included in 
the study. 
The total number of 132 patients suitable for data analysis consisted of 51, 48 and 
33 patients with Stage 1/2, 3 and 4 HIV-infection, respectively. The initial AIDS-
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defining illness of Stage 4 patients and the time period between the initial AIDS-
defining illness and enrollment into this study, is illustrated in Table 7.1. 
Table 7.1 Initial AIDS-defining illnesses of Clinical Stage IV patients (n=33) 
AIDS-defining Illness 
Extrapulmonary Tuberculosis 
Pneumocystis carinii pneumonia 
Cryptococcosis 
Toxoplasmosis 













7 .1 Demographic characteristics 
Time period between AIDS-
defining illness and study 
enrollment (months) 
11.2±10.7 




7.3 ± 10.2 
1.7 ± 2.9 
0 
The mode of HIV-transmission for all subjects was heterosexual transmission. 
Table 7.2 shows that women are overrepresented in the sample, which reflects the 
current trend in the HIV-epidemic in South Africa. There were no significant 
differences between the three clinical stage categories for gender or age. 
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Due to logistic problems, variables such as educational level, current 
employment, the availability of electricity or a refrigerator are only available on 118 
patients. However, sub-analysis revealed no significant differences in terms of 
plasma retinal levels between those patients on whom information was available 
and the total number of patients in each clinical stage category. 
No differences between the clinical stage categories were noted in terms of type of 
housing and the availability of electricity or a refrigerator. Seventy seven percent 
(77%) of subjects with stage 4 disease did not hc1vP. hi!;h sr.honl erl1_1r.~tinn 
compared to 41 % of subjects with early disease (p < 0.01 ). Only thirteen percent 
(13%) of stage 4 subjects and 14% of stage 3 subjects were employed at the time 
of the study, compared to 43% of subjects with early disease (p < 0.05). 
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Table 7.2 Characteristics of HIV-positive individuals with WHO Clinical 
Stage I to IV HIV-Infection 
WHO STAGE I & II WHO Stage Ill WHO Stage IV 
Age (n=132) (n=51) (n =48) (n = 33) 
32.9 ± 9.5 33.9 ± 10.6 32.5 ± 10.9 
Gender 
Male 15/51 (29%) 17/48 (35%) 15/33 (45%) 
Female 36/51 (71 %) 31/48 (65%) 18/33 (55%) 
Education (n=118) 
< Std 5 6/44 (14%) 6/44 (14%) 9/30 (30%) 
Std 5 12/44 (27%) 22/44 (50%) 14/30 (47%) 
Std 8 13/44 (30%)* 11/44 (25%)* 4/30 (13%)* 
Std 10 10/44 (23%)* 4/44 (9%)* 2/30 (7%)* 




Yes 19/44 (43%)* 6/44 (14%)* 4/30 (13%)* 
No 25/44 (57%) 38/44 (86%) 26/30 (87%) 
Electricity 
(n=118) 
Yes 31/44 (70%) 33/44 (75%) 20/30 (67%) 
No 13/44 (30%) 11/44 (25%) 10/30 (33%) 
Refrigerator 
(n=118) 
Yes 20/44 (45%) 16/44 (36%) 8/30 (27%) 
No 24/44 (55%) 28/44 (64%) 22/30 (73%) 
* p < 0.01 
7.2 Retinal 
Table.7.3 shows that the median plasma retinal levels are significantly different 
between clinical stages amongst all the patients (p=0.002). The median plasma 
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retinal level for patients with early disease was 34µg/dl, compared to 30.7 and 
23.7 µg/dl for patients with Stage 3 and 4 disease, respectively. The median 
plasma retinal levels between clinical stage categories is also significantly different 
in the case of male (p=0.001) and female (p=0.02) patients. 
The plasma retinal levels of male patients with Stage 1 and 2 HIV-infection were 
significantly higher than female patients being 46.4 ± 15.8 µg/dl (median = 
42.9µg/dl) compared to 30.8 ± 10.4 µg/dl (median = 30.1 µg/dl), respectively. 
However, the plasma retinal levels of male and female subjects within the other 
clinical strata in the sample, were similar (Table 7.3). 
The median plasma retinal level of Stage 4 patients with HIV-wasting syndrome 
(n=3) at study entry was 21.1 µg/dl, compared to the median level of 23.7 µg/dl 
for all Stage 4 patients (NS). The median plasma retinal level of Stage 4 patients 
with extrapulmonary tuberculosis (n=7) at study entry was 20.6 µg/dl, however, 
this difference was also not statistically significant. 
In Stage 3 patients the median plasma retinal level of subjects with oral 
candidiasis (n=13) at study entry was 27.4 ~tg/dl, compared to the median level 
of 30.7 µg/dl for all stage 3 patients (NS). 
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Table 7.3 Plasma retinol levels of patients with WHO Stage I to IV HIV-
infection 
WHO Stage I and II WHO Stage Ill (n WHO Stage IV (n p 








Median 34.0 30.7 23.7 0.002 
MALES 
(n=47) 46.4 ± 15.8 28.3 ± 10.2 26.9±11.7 
Mean± SD 
Median 42.9* 29.2 24.3 0.001 
FEMALES 
(n=85) 30.8 ± 10.4 31.6 ± 11.8 23.8 ± 10.6 
Mean± SD 
Median 30.1* 31.6 21.9 0.02 
* p < 0.001 
The proportion of patients with borderline plasma retinal levels (< 30 µg/dl) versus 
low plasma retinal levels (<20 µg/dl) in each clinical stage category is shown in 
Table 7.4. 
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Table 7.4 The proportion of patients with WHO Stage I to IV HIV-
infection with a borderline (< 30 µg/dl) versus a low (< 20 µg/dl) plasma 
vitamin A status 
WHO Stage I WHO Stage Ill WHO Stage IV 2 X trend 
& II 
Plasma retinal 
< 30 µg/dl 
(< 1.05 µmol/1) 
Both sexes 20/51 23/48 26/33 0.0007 
(n=132) (39%) (48%) (79%) 
Males 2/15 9/17 12/15 0.0003 
(n= 47) (13%) (53%) (80%) 
Females 18/36 14/31 14/18 0.1 
(n=85) (50%) (45%) (78%) 
WHO Stage I WHO Stage Ill WHO Stage IV 2 X trend 
& II 
Plasma retinal 
< 20 µg/dl 
(< 0.7 µmol/1) 
Both sexes 7/51 8/48 11/33 0.04 
(n=132) (14%) (17%) (33%) 
Males 0/15 3/17 3/15 
(n=47) (18%) (20%) 
Females 7/36 5/31 8/18 0.08 
(n=85) (19%) (16%) (44%) 
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Table 7.4 shows that there is a significant linear increase in the proportion of 
patients with a borderline retinol status(< 30 µg/dl) from those with early disease 
to those with advanced disease., especially in the case of male patients. 
Thirteen percent (13%) of male patients with early disease had a borderline 
retinal status, compared to 53% and 80% of Stage 3 and 4 patients, respectively 
(p=0.003). 
A higher proportion of female patients with early disease displayed a borderline 
retinol status compared to the male patients, namely 50%. Therefore, a significant 
linear trend across clinical stage categories was not apparent in female subjects. 
7 .3 Body weight and Body Mass Index {BMI) 
No gender differences in terms of body weight and BMI within the three clinical 
staging categories, were demonstrated. The relationship between clinical stage and 
body weight or BMI was significant (p=0.02) (Table 7.5). 
Although the data is incomplete in terms of BMI, only 6/29 (21%) Stage 4 patients 
had a BMI < 18.5 and could therefore be categorised with chronic energy 
malnutrition. 
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Table 7.5 Body weight and Body Mass Index (BMI of patients with 
WHO Stage I to IV HIV-infection 
WHO Stage I WHO Stage Ill WHO Stage IV p 
& II 
Weight (Kg) (n=51) (n=48) (n=33) 
Mean± SD 69.0 ± 19.8 61.2±11.0 57.3 ± 13.5 
Median 66 60.5 58.0 0.01 
BMI (kg/m2) (n =45) (n = 42) (n = 29) 
' Mean± SD 26.4 ± 6.5 23.7 ± 4.8 21.9 ± 4.5 
Median 24.5 22.7 21.7 0.01 
7 .4 CD4 lymphocyte count, CD4:CD8 lymphocyte ratio 
and Total lymphocyte count (TLC) 
Six blood samples were insufficient for full blood count analysis, therefore data is 
presented on 126 subjects. For 129 patients the C04:CD8 lymphocyte ratio could 
be calculated. 
No gender differences in terms of CD4 lymphocyte count, CD4:CD8 lymphocyte ratio 
or TLC within the three clinical staging categories, were demonstrated. Table 7.6 
shows a significant difference between the median CD4 lymphocyte levels and 
C04:CDa lymphocyte ratios (p < 0.001) between the three clinical stage categories. 
The difference in the median Total lymphocyte counts approached significance 
between the three categories (p=0.1 ). 
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Table 7.6 CD4 lymphocyte levels , CD4: CDS lymphocyte ratio and Total 
lymphocyte count (TLC) of patients with WHO Stage I to IV HIV-infection 
(n=126) 
WHO Stage I WHO Stage Ill WHO Stage IV p 
& II (n = 47) (n = 32) 




Mean± SD 403 ± 198 205 ± 177 155 ± 136 




Mean± SD 0.5 ± 0.3 0.2 ± 0.2 0.1 ± 0.1 






Mean± SD 1883 ± 757 1583±701 1573 ± 948 
Median 1820 1464 1392 0.1 
C04 lymphocyte levels and the C04:CD8 ratio were dichotomised to < 200, 2 200 
cells/µI and ratios of< 0.15, 2 0.15, respectively. In patients with CD4 lymphocyte 
levels of less than 200 cells/µI the median retinal level was 27.1 µg/dl (28 ± 14.7 
µg/dl), compared to 34 µg/dl (34 ± 13.3 µg/dl) in patients with CD4 lymphocyte 
levels above or equal to 200 cells/µI (Fig. 7.1) (p=0.01 ). The median retinal level of 
patients with a C04:CDa ratio of less than 0.15 was 25.4 µg/dl (26.3 ± 11.5 µg/dl) 
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versus 32.4 µg/dl (33.3 ± 13.3 µg/dl) in patients with a ratio equal or above 0.15 
(Fig 7.2) (p=0.005). 
VVhen TLC was dichotomised to < 1250 and :2: 1250 cells/µI the median retinal 
levels in the respective categories were 27.8 µg/dl (29 ± 14.7 µg/dl) and 31.6 µg/dl 
(32.4 ± 12.2 µg/dl), respectively (Fig. 7.3). This difference in retinal levels 
approached significance (p=0.1 ). 
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A significant association between plasma retinal and C04 lymphocyte levels (r = 
0.27; 95% Cl: 0.1; 0.43) and the C04 :CD8 ratio (r=0.33 95 Cl%: 0.1; 0.42) for 126 
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7.5 C-reactive protein {CRP) 
All the subjects with the exception of one subject, did not show highly elevated CRP 
levels above 1 OOmg/1. One patient with clinical stage 3 disease had a CRP level of 
174 mg/I. This observation was not excluded. A higher proportion of patients with 
Stage 3 or 4 disease (48%; 42%) had CRP levels z 10mg/l, compared to patients 
with early disease (23%). (Table 7.7). 
Table 7.7 CRP levels of patients with WHO Stage I to IV HIV-infection 
(n=132) 
WHO Stage I WHO Stage Ill WHO Stage IV 2 X trend 
& II (n = 48) (n = 33) 
(n = 51) 
CRP 
< 10 mg/I 39 25 19 3.93 
(77%) (52%) (58%) (p=0.05) 
z 10 mg/I 12 23 14 
(23%) (48%) (42%) 
7.5.1 CRP and retinal 
CRP levels were then categorized according to the following categories: < 10 mg/I; 
10-40 mg/I and > 40 mg/I. Plasma levels of retinal were examined according to 


















FIG. 7.6 Plasma retinol levels according to different 















The mean retinal level of patients with CRP levels above 40 mg/I was 19.7 ± 13.3 
mg/I (median=16.8 mg/I), compared 30.3 ± 14.7 mg/I (median = 27.3mg/l) in 
patients with CRP levels between 10 and 40 mg/I and 32.4 ± 11.5 mg/I (median= 
30.2 mg/I) in patients with CRP levels below 10 mg/I, respectively. The median 
retinal levels across the different categories of CRP was statistically significant 
(p=0.04). 
7.6 Retinol-binding protein (RBP) 
A strong correlation between plasma retinal and RBP levels for all the subjects was 
shown using the Spearman's correlation coefficient (Fig.7.7) 
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Plasma RBP levels were also categorised according to the following categories of 
CRP , namely < 10 mg/I; 10-40mg/l and > 40 mg/I (Fig. 7.8). No statistical 
differences in terms of plasma RBP levels across the three categories of CRP 
were found (p=0.94). 
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FIG.7.8 Plasma retinol binding protein (RBP) levels according 
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(vii) Zinc 
Two blood samples were contaminated with zinc during the blood sampling 
procedure and were identified as extreme values and therefore data is presented 
on 130 subjects. The difference in the median zinc levels between clinical stage 
categories approached significance (p=0.06) (Table 7.8). Plasma zinc levels were 
similar between genders within the three clinical staging categories. 
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Table 7.8 Plasma zinc levels of patients with WHO Stage I to IV HIV-
infection (n=130) 
WHO Stage I and II WHO Stage Ill (n WHO Stage IV (n p 




Mean±SD 85.8 ± 22.6 79.1 ±21.6 74.7±18.1 
Median 84 78 72 0.06 
Plasma zinc levels were also categorised according to the following categories of 
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FIG. 7.9 Plasma zinc levels according to different 














The relationship between plasma zinc and the three categories of CRP was 
similar to that observed between plasma retinal and CRP, although not statistically 
significant. 
The mean zinc level of patients with CRP levels above 40 mg/I was 67.4 ± 14.9 
µg/dl (median=64 µg/dl), compared to 77.9 ± 22.7 µg/dl (median = 78 µg/dl) in 
patients with CRP levels between 10 and 40 mg/I and 83 ± 21 µg/dl (median = 81 
µg/dl) in patients with CRP levels below 10 mg/I, respectively (p=0.1 ). 
7. 7 Multivariate analysis with clinical stage IV (AIDS) as 
dependent variable 
Univariate analysis showed a significant association between plasma retinal with 
Clinical Stage 4 HIV-infection or AIDS as dependent variable. Plasma retinal levels 
were dichotomised as < 30µg/dl; ~ 30 µg/dl and as < 20µg/dl; ~ 20 µg/dl. Risk 
factors for the development of AIDS reported in the literature such as CD4 
lymphocyte count, CD4:CD8 lymphocyte ratio, haemoglobin, haematocrit and serum 
zinc levels were also found to be significant on univariate analysis. .Other factors 
which were significantly associated with Clinical Stage 4 were body weight and 
BMI. Total lymphocyte count, CRP levels, platelet count, gender and socio-
economic variables such as employment and the availability of a refrigerator were 
not significant during univariate analysis. 
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A strong correlation between retinal and RBP levels (r= 0.62; p<0.001) resulted 
in the inclusion of only retinal in the final multivariate model. Due to collinearity 
between CD4 lymphocyte count and CD4:CD8 lymphocyte ratio (r=0.78; p=0.0001) 
two multivariate models are presented including each of these variables. 
Haemoglobin and haematocrit were also highly correlated (r=0.97; p=0.0001) and it 
was decided to use haemoglobin in the final model. Haemoglobin was 
dichotomised to< 12g/dl and ?: 12 g/dl, respectively. In a previous study examining 
the role of serum retinal with survival in AIDS patients, haemoglobin was excluded 
from the final multivariate model due to collinearity with serum retinal (Semba 
1995). In our study haemoglobin was included in the final model, since the 
Spearman's correlation coefficient for haemoglobin with retinal was 0.43 (p<0.001 ). 
Because of the incompleteness of the data in terms of BMI, it was decided to 
include body weight in the final model since these variables were also highly 
correlated (r=0.83;p<0.001 ). 
No interaction terms between any of the variables were found to be significant. 
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Table 7.9 Unadjusted and adjusted odds ratios (OR) and 95% 
confidence intervals (Cl) of logistic regression for potential 
risk factors as predictors of Clinical Stage IV HIV-infection or 
AIDS. 
MODEL 1 (n=125) 
Variable ORunadjusted (95%CI) ORAdjusted (95%CI) 
Plasma retinol 4.7 (2.9-7.6) 3.3 (2.0-5.6) 
< 30 µg/dl 
CD4 count 3.7 (2.4-5.7) 2.5 (1.6-4.0) 
< 200 cells/µI 
Haemoglobin 2.6 (1.7-4.1) 1.5 (0.9-2.4) 
< 12 g/dl 
Plasma zinc 2.5 (1.7-3.9) 1.7 (1.07-2.8) 
(< 70 µg/dl) 
Body weight 0.83 (0.77-0.91) 0.95 (0.86-1.01) 
(per 5kg increase) 
58 
Table 7.10 Unadjusted and adjusted odds ratios (OR) and 95% 
confidence intervals (Cl) of logistic regression for potential 
risk factors as predictors of Clinical Stage IV HIV-infection or 
AIDS. 
MODEL 2 (n=125) 
Variable ORunadjusted (95%CI) ORAdjusted (95%CI) 
Plasma retinol 4.7 (2.9-7.6) 2.9 (1.7-4.9) 
< 30µg/dl 
CD4:CD8 ratio 6.1 (3.9-9.5) 3.9 (2.4-6.5) 
< 0.15 
Haemoglobin 2.6 (1.7-4.1) 1.5 (0.94-2.5) 
<12g/dl 
Plasma zinc 2.5 (1.7-3.9) 1.3 (0.8-2.2) 
(< 70 µg/dl) 
Body weight 0.83 (0.77-0.91) 0.96 (0.88-1.05) 
(per 5kg increase) 
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The association between borderline plasma retinal levels(< 30µg/dl) and Stage 
4 disease remained significant when adjusted for potential confounding variables 
such as CD4 lymphocyte count, C04:CD8 lymphocyte ratio, haemoglobin, zinc and 
body weight. 
The association between low plasma retinal levels (<20µg/dl) and Stage 4 disease 
was significant on univariate analysis, but did not remain significant when adjusted 
for potential confounding variables. This could be explained by the small number of 
patients with retinal levels of less than 20 µg/dl, resulting in a lack of statistical 
power. 
Both models are highly significant (p < 0.001). Model 7.10 shows a better model fit 
than model 7.9, using the -2 Log Land the AIC criterion (See Appendix). Residual 
analysis of both models identified four observations that were not well explained by 
the model. These observations were Stage 4 subjects who had retinal levels above 
30µg/dl, C04 lymphocyte counts above 200/µI, or C04:CD8 lymphocyte ratio above 
0.15, plasma zinc levels above 70 µg/dl and haemoglobin levels above 12g/dl. 
7 .8 Multivariate analysis with retinal as dependent 
variable 
In this logistic regression model, plasma retinal levels of< 30 ~tg/dl was used as the 
outcome variable. Predictor variables of a borderline retinal status that were 
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examined during univariate analysis included variables which are available in 
routine clinical practice such as TLC, C04 lymphocyte count or C04:CDs 
lymphocyte ratio, body weight and BMI, haemoglobin, haematocrit, CRP and zinc 
levels. 
Due to collinearity between CD4 lymphocyte count and CD4:CDs lymphocyte 
ratio(r=0.78; p=0.0001) two multivariate models are presented including each of 
these variables, as in section 7.6. Haemoglobin levels and body weight were 
included in the final multivariate model, as in section 7.6. 
No interaction terms between any of the variables were found to be significant. 
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Table 7.11 Unadjusted and adjusted odds ratios (OR) and 95% 
confidence intervals (Cl) using logistic regression analysis for 
predictors of borderline plasma retinol levels(< 30 µg/dl) 
MODEL 1 (n=126) 
Variable ORunadjusted (95%CI) ORAdjusted (95%CI) 
WHO Clinical Stage IV 4.8 (3-7.6) 3.4 (2.1-5.7) 
CD4 count 3.6 (2.4-5.6) 1.4 (0.9-2.1) 
< 200 cells/µI 
Haemoglobin 3.3 (2.3-4.8) 2.4 (1.6-3.5) 
<12g/dl 
Body weight 0.82 (0.77-0.98) 0.87 (0.80-0.93) 
(per 5kg increase) 
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8 Discussion 
8.1 Retinol and clinical stage 
Our study demonstrated that the proportion of patients with borderline plasma 
retinal levels (< 30 µg/dl) is greater in symptomatic disease, specifically in Clinical 
Stage IV disease or AIDS. The confounding effect of opportunistic infections was 
limited in this study by means of the study exclusion criteria and by clinical review of 
the data. 
79% of all AIDS patients had borderline retinal levels(< 30 µg/dl) compared to 39% 
of patients with early disease (p <0.001). 33% (11/33) of AIDS patients had low 
retinal levels (< 20 µg/dl) compared to 14% (7/51) of patients with early disease 
(p=0.04). In a study by Semba et al. borderline retinal levels .(< 30 µg/dl) were 
present in 50% of AIDS patients at their last visit before death (1). The mean 
plasma retinal level of the AIDS patients in our study (25.2 ± 11.1 µg/dl) was 
significantly lower than previously reported in hospitalised AIDS patients not 
receiving vitamin A supplementation in an industrialised country (36.5 ± 22.53 
µg/dl) (p <0.01) (2). 
Only four patients in this study were vitamin A deficient. Three patients with Stage 
3 disease and one patient with Stage 4 disease demonstrated plasma retinal levels 
of less than 10 ~tg/d I. 
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Table 7.12 Unadjusted and adjusted odds ratios (OR) and 95% 
confidence intervals (Cl) using logistic regression analysis for 
predictors of borderline plasma retinal levels (< 30 µg/dl) 
MODEL 2 (n=126) 
Variable ORunadjusted (95%CI) ORAdjusted (95%CI) 
WHO Clinical Stage IV 4.8 (3-7.6) 3.0 (1.8-5.1) 
CD4:CD8 ratio 3.6 (2.4-5.6) 2.0 (1.2-3.2) 
< 0.15 
Haemoglobin 3.3 (2.3-4.8) 2.4 (1.6-3.6) 
< 12 g/dl 
Body weight 0.82 (0.77-0.98) 0.88 (0.81-0.94) 
(per 5kg increase) 
WHO Stage 4 disease or AIDS was independently associated with a threefold 
increased risk of borderline plasma retinal levels (< 30 µg/dl) after controlling for 
CD4 lymphocyte count or the CD4:CD8 lymphocyte ratio, haemoglobin levels and 
body weight. Haemoglobin levels of less than 12 g/dl and body weight were both 
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also independently associated with low retinal levels. C04 lymphocyte counts of 
less than 200 cellshtl and a CD4:CDs lymphocyte ratio of less than 0.15 were 
significant on univariate analysis, but were not significant in the multivariate model. 
TLC was not associated with retinal levels during univariate analysis. Plasma zinc 
and CRP levels were evaluated in the multivariate model, but did not contribute 
significantly to the model, nor did it change the adjusted odds ratios of any of the 
covariates in the model. 
Both models are highly significant (p <0.001). Model 7.12 shows a better model fit 
than model 7.11, using the -2Log Land the AIC criterion (See Appendix). Residual 
analysis showed that only one observation could not be explained by the model. 
This observation was a subject with stage 4 disease with a retinal level of 43 µg/d. 
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A recent study in a local urban African population has shown that selected 
proxies for higher socio-economic status such as formal housing, the availability of 
electricity and the presence of a refrigerator were associated with a higher 
micronutrient intake in women aged 19-44 years, especially with respect to vitamin 
A (3). Our study showed that 43% of patients with early disease were employed at 
the time of the study, compared to 13% and 14% of patients with stage 3 and stage 
4 disease, respectively. This could be explained by the nature of HIV disease. As 
the disease progresses, so unemployment due to disability increases. Also, 27% of 
patients with advanced disease had a refrigerator compared to 45% of patients with 
early disease, although this was not statistically significant. Therefore, although 
dietary intake of micronutrients and specifically vitamin A intake was not assessed, 
it is likely that socio-economic factors contributed to a poorer micronutrient status in 
those patients with advanced disease who were included in our study. 
The difference in plasma retinal levels between male and female patients with early 
disease in our study cannot be readily explained. No gender differences are 
apparent in the other two clinical stage categories in terms of plasma retinal. Socio-
economic variables between male and female patients with early disease, were 
similar. We were unable to assess any differences in parity between female 
patients in the three clinical categories in this study against the background of 
increased physiological needs during pregnancy and lactation (4). 
It has been suggested that diarrhoea may contribute to low retinal levels in HIV 
disease. In a study by Semba et al. patients with histories of oral thrush and 
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diarrhoea were more likely to be vitamin A deficient (1 ). In our study we were 
unable to show any significant finding because of the inclusion of a very small 
number of patients with diarrhoea. No significant differences in plasma retinal 
levels between patients with oral or oesophageal thrush compared to the rest of the 
Stage 3 or Stage 4 patients, were found. 
8.2 Retinol and immune function 
Retinoids are known to enhance cellular differentiation and have an important role 
in the differentiation of haemopoietic cells and other cell lineages (5). Thus, retinal 
status may be important for the differentiation of CD4 cells. 
Lower CD4 counts have been associated with lower retinal levels amongst HIV-
seropositive and HIV-seronegative individuals (6,7). In this study lower retinal 
levels were associated with a low CD4 count and CD4:CD8 lymphocyte ratio. 
Patients with CD4 counts of< 200 cells/µL had a mean plasma retinal of 28 µg/dl 
(median= 27.1 µg/dl) compared with a mean level of 34 µg/dl (median 33.6 µg/dl) 
in patients with CD4 counts ~ 200 cells/µL (p=0.01 ). Plasma retinal levels were 
slightly lower in patients with a CD4:CD8 lymphocyte ratio of < 0.15 when compared 
with those with a low CD4 count a (median= 25.4 µg/dl). The association between 
plasma retinal levels and CD4 counts and CD4:CD8 lymphocyte ratios was 
confirmed by means of significant Spearman's correlation coefficients (r=0.27 95% 
Cl: 0.1 ;0.43 ; r=0.33 95% Cl: 0.1 ;0.42). 
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Many infectious diseases are associated with a lowered C04 lymphocyte levels, 
CD4: CD8 lymphocyte ratio such as HIV, Epstein-Barr virus, measles, 
cytomegalovirus, candidosis and pneumonia. High dose vitamin A 
supplementation in children with measles and in post-operative adult patients have 
been associated with an increase in absolute T lymphocyte cell count (8,9). In HIV 
disease, high dose vitamin A supplementation has been shown to reduce the 
morbidity associated with diarrhoeal disease in HIV-infected children (OR = 0.51; 
95% Cl = 0.27,0.99) (10). Another clinical trial investigated the effect of high dose 
vitamin A supplementation on the immune function of 75 children with AIDS without 
active infections. Supplementation was associated with a significant increase in 
serum retinal, absolute lymphocyte count, CD4 and CD29 counts at 4 weeks after 
supplementation (11 ). 
Short term intervention studies in HIV-infected individuals have suggested that ~-
carotene supplementation may increase white blood cell count and CD4 counts 
(12). A recent clinical trial conducted amongst 72 HIV-positive patients failed to 
demonstrate any significant effect of ~-carotene supplementation after 3 months on 
T cell subsets and other immune markers. Goodley et al. suggests that the addition 
of a multivitamin supplement to both arms of the study may have masked any 
differences between the two groups, since sufficient retinal concentrations were 
observed in both groups (13). 
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8.3 Retinal and the acute phase response 
lnterleukin-6 (IL-6) is thought to be the main mediator of CRP production, one of the 
major acute-phase proteins (14). HIV-infection per se is known to stimulate 
macrophages resulting in increased IL-6 levels, even in asymptomatic HIV-positive 
patients (15). It has been suggested that the IL-6 level increases with the 
progression of HIV-infection (16). However, normal CRP levels (< 10 mg/I) have 
been reported in asymptomatic HIV-positive subjects and in HIV-positive subjects 
after recovering from pneumonia, suggesting that increased IL-6 levels alone 
seems insufficient to increase CRP production (17, 18). 
In contrast to the studies cited above, Tang et al. showed in a cohort of 312 men of 
whom 81 % were asymptomatic, that 55% had elevated serum CRP levels (~ 8 
mg/I) (19). In our study there was an association between raised CRP levels (~ 10 
mg/I) and the clinical stage of disease. The proportion of subjects with raised CRP 
levels who were asymptomatic was 23%, compared to 48% and 42% of subjects 
with Stage 3 and 4 disease, respectively (p=0.05). It should be noted that in the 
majority of our subjects the CRP levels were only mildly elevated. One patient with 
clinical stage 3 disease showed highly elevated CRP levels (> 100 mg/I). This 
could indicate the presence of an underlying infection in this subject despite the 
exclusion of patients with pyrexia in our study. In the majority of our subjects, a 
mildly raised CRP level may be attributable to a direct effect of HIV-1 activity. 
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Our study showed that the median retinal level of patients who had CRP levels 
greater than 40 mg/I was significantly lower (16.8 µg/dl) than in patients with CRP 
levels between 10 and 40 mg/I (27.3 µg/dl) and compared to those with CRP levels 
within the normal range (30.2 µg/dl). This suggests that the acute phase response 
contributed to low plasma retinal levels only in a small number of our subjects 
(n=7). Tang et al. showed despite their observation that CRP levels were elevated 
in 55% of their subjects, that the retinal levels were in the high-normal range 
(median= 70 µg/dl). In view of this, they suggested that a better vitamin A status 
can protect against drops in serum retinal into the deficient range during the acute 
phase response (19). 
Serum zinc levels decrease during acute illness or infection due to the presence of 
the acute phase response and is negatively correlated with CRP levels (20,21,22). 
Decreased serum zinc levels have been reported in AIDS patients with 
opportunistic infections (23). Graham et al. showed in a nested case control study 
embedded in a cohort, that serum zinc levels in seropositive individuals who 
progressed to AIDS were significantly lower when compared to those in whom the 
disease did not progress. He also showed in a logistic regression model that low 
serum zinc and high serum copper levels predicted progression to AIDS 
independently of baseline CD4 lymphocyte count, age and the calorie-adjusted 
dietary intakes of both nutrients. Serum zinc and copper are both acute phase 
reactants and Graham et al. postulated that the observed effect of zinc and copper 
on disease progression was attributable to a direct effect of HIV-1 viral activity 
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resulting in the acute phase response, since patients with opportunistic infections 
were excluded in their study. Markers of the acute-phase response such as CRP 
levels, were not measured in their study (24 ). 
Although not statistically significant, our study demonstrated a similar relationship 
between plasma levels of CRP and zinc to that observed between plasma retinal 
and CRP (p=0.1 ). In addition, the median plasma zinc level was lower in subjects 
with advanced disease compared to subjects with early disease, this difference 
approached significance (p=0.06). Therefore, our results suggest that the decrease 
in plasma zinc status with advancing disease could only be partly explained against 
the background of the acute phase response as a result of HIV- viral activity. 
This study demonstrates that markers of the acute phase response such as raised 
CRP levels were associated with low plasma retinal levels in a small number of 
subjects. Other contributory factors such as a poor dietary intake, malabsorption 
and regular intercurrent infections could result in lowered serum retinal levels due to 
depleted hepatic retinal stores in patients with advanced HIV-disease. 
8.4 Multivariate analysis with clinical stage IV (AIDS) as 
dependent variable 
Low levels of retinal (< 30µg/dl) was independently associated with a 3-fold 
increase in the risk of having AIDS in this study, after adjusting for potential 
confounding and intermediate variables such as CD4 lymphocyte count, CD4:CD8 
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lymphocyte ratio, haemoglobin, zinc and body weight (Table ). CD4 counts of< 
200 cellshtl and a CD4:CD8 lymphocyte ratio of< 0.15 were associated with a 2.5 
and 4-fold increase in the risk of having AIDS. Haemoglobin, zinc and body weight 
were not independently associated with AIDS. 
Decreased CD4 T-cells and a decreased CD4 to CDs lymphocyte ratio have both 
been shown to be strong predictors of the progression of HIV-disease to AIDS 
(25,26,27,28,29). Furthermore, it has been suggested that a low TLC is also an 
independent predictor of HIV-disease progression and a high correlation between 
CD4 T-cells and TLC has been demonstrated in patients with symptomatic HIV-
disease (29,30). In this study, TLC was not significantly associated with Stage 4 
disease on univariate analysis. 
Semba et al. showed that wasting occurred in 38% of AIDS patients at their last 
visit before death. His study showed that low retinal levels (OR=4.6; 
95%Cl:1.8;11.3) and wasting (8.8; 95%Cl:2.7-28.2) were both independent 
predictors of mortality (1 ). In our study only 6/29 (21 %) of subjects with AIDS had a 
low BMI (< 18.5). Wasting was therefore not likely to be a strong confounder in the 
relationship between low plasma retinal levels and AIDS in our study. 
The inclusion of haemoglobin levels < 12g/dl in the multivariate analysis resulted in 
a 8-10% decrease in the regression coefficient of retinal in both models. Reduced 
haemoglobin and haematocrit levels have been associated with low serum retinal 
levels in HIV-infected patients (1,6). Haemoglobin may be an intermediate 
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variable in the relationship between vitamin A and AIDS, since haematopoiesis is 
vitamin A dependent. It appears that vitamin A-deficient children are prone to the 
development of a mild iron-deficiency anaemia and that vitamin A supplementation 
may improve haematopoiesis in children who are vitamin A deficient . Vitamin A 
may therefore be involved in the regulation of iron release from hepatic stores 
(31,32,33). 
However, the development of anaemia in advanced disease may signify the degree 
of involvement of the bone marrow via direct infection of progenitor cells by HIV 
(34 ). Several studies have shown that a low haematocrit or haemoglobin are 
associated with progression of HIV-disease or a decrease in CD4 counts and 
shorter survival in AIDS patients (25,35,36,37). 
Although plasma zinc levels < 70 µg/dl was significantly associated with AIDS 
during univariate analysis, we were unable to demonstrate any significant 
relationship after adjusting for the other covariates in the multivariate model. 
The inclusion of CRP levels into the multivariate model did not contribute 
significantly to the model, nor did it change the adjusted odds ratio of any of the 
covariates in the model. The lack of a significant association between raised CRP 
levels and AIDS is similar to the findings of Tang et al. who showed in a prospective 
study that raised CRP levels were not significantly associated with an increased 
risk of progression to AIDS (19). 
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Although our study showed that low serum retinal levels were associated with 
clinical stage IV HIV-disease or AIDS after controlling for potential confounding 
factors such CD4 lymphocyte count, the cross-sectional design precludes causal 
inferences about this association. 
8.5 Multivariate analysis with retinol as dependent 
variable 
In this study subjects with WHO clinical stage 4 disease or AIDS had a threefold 
risk of having retinal levels less than 30 µg/dl, after adjusting for CD4 lymphocyte 
count, body weight and haemoglobin levels. 
As mentioned before, because haematopoiesis is vitamin A dependent, it is 
therefore not surprising that low haemoglobin levels were independently associated 
with low retinal levels in the multivariate model. The confounding effect of PEM 
was controlled by the inclusion of body weight in the final multivariate model. 
CD4 lymphocyte count and the CD4:CD8 lymphocyte ratio were not independent 
predictors of a low retinal status in this study, after adjusting for clinical stage. 
Clinical stage was therefore a stronger predictor of a low vitamin A status in this 
study. There was also no relationship between TLC and retinal. 
Finally, raised CRP levels and lowered zinc levels were not significantly predictors 
of retinal levels less than 30 µg/dl. 
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9 Limitations 
9.1 Study design 
The ideal study design to investigate risk factors such as low plasma vitamin A 
status with the development of AIDS as endpoint or outcome measure would be a 
prospective cohort study. Although logistic regression indicated a significant 
relationship between plasma retinal and advanced disease, the cross-sectional 
study design used precludes any causal inferences about the association between 
plasma vitamin A status and the progression of HIV-disease. A modification of the 
basic cohort design involves inserting a case-control study into a prospective cohort 
study, which is often referred to as a nested case-control design. For example, 
blood samples could be collected from a subgroup of the cohort at baseline and at 
certain intervals during the follow-up period. VVhen a sufficient number of AIDS 
cases had accrued, the blood results for these cases could then be compared with 
those subjects who had not yet developed AIDS (controls). Such an approach 
would be particularly efficient, in terms of both time and cost, compared to a cohort 
design. 
Furthermore, the validity of this study may also be criticised due to the lack of HIV-
seronegative controls. 
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9.2 Sample size 
A precision level of 5% for the estimation of sample estimates is viewed as an 
acceptable level of precision. However, a sample size at a precision level of 5% 
was not attainable within the specified study period and therefore the precision of 
this sample was reduced to 7.5%. 
Statistical significance is dependent on sample size and is derived from the 
standard error, which is directly related to the variability of the observation. The 
exclusive use of the 95% confidence level (p <0.05) to assess significance has 
obvious drawbacks which may result in potentially clinically important observations 
being discarded (type II error). It has been suggested that the construction of 
confidence intervals provides a better interpretation of an association as it provides 
an indication of the magnitude of the association. Therefore, odds ratios derived 
from logistic modelling are presented as 95% confidence intervals. 
Non-parametric statistics was used in this study due to the non-normality of the 
data. An obvious drawback that resulted from this is that there are no non-
parametric post-hoc tests available for further investigation of a significant 
relationship between more than two variables. 
Finally, the external validity or generalisability of this study to the HIV-positive 
population attending health facilities in South Africa is limited by the small sample 
size. 
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9.3 Bias and validity of instruments 
Selection bias in this sample may explain the observed differences in selected 
proxies for socio-economic status such as educational status, employment and 
fridge ownership between subjects with early and advanced disease. On the other 
hand, it seems feasible that subjects with advanced disease would be more likely to 
become unemployed than subjects with early disease. 
Plasma retinal is a commonly used biochemical measure of vitamin A status. It 
should be remembered that plasma levels only become predictive of an individual's 
status when body reserves has been critically depleted. Therefore, the Relative 
Dose Response test which was not employed in this study, show greater validity as 
a marker of marginal vitamin A stores than a single plasma sample. Plasma zinc 
levels show diurnal and postprandial variation and therefore the validity of plasma 
zinc levels in this study may also be critized in view of the fact that fasting blood 
samples were not taken. 
Another limitation of this study is that the status of other micronutrients were not 
assessed. Deficiencies of other micronutrients such as vitamin E, B6 , B12 and 
selenium may also influence cell-mediated immunity in HIV disease. 
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10 Conclusions and 
Recommendations 
This study demonstrated that a significant proportion of subjects, especially those 
with advanced disease, presented with low plasma retinal levels in the absence of 
opportunistic infections, which highlights the potential magnitude of this public 
health problem. 
Controlled trials are required to evaluate the effect of vitamin A supplementation on 
the progression of HIV disease and survival of AIDS patients in developing 
countries such as South Africa where the majority of the HIV- infected population 
are likely to have a marginal vitamin A status. High dose vitamin A 
supplementation has been associated with improved immune function in children 
with measles and AIDS and has also been associated with reduced morbidity in 
HIV-infected children (1,2,3). However, a recent clinical trial showed that 
multivitamins, not vitamin A, resulted in a significant increase in immune function of 
pregnant HIV-infected women. Multivitamin supplementation also decreased the 
risk of foetal death, low birthweight, severe preterm birth and small for gestational 
age. With regard to the lack of a beneficial evidence for the role of vitamin A, Fawzi 
et al. suggests that serum retinal concentrations are markers of the stage of HIV-
83 
disease or intermittent infections due to the acute phase response, rather than 
causally related to adverse birth outcomes (4). The results of similar trials which 
are being conducted in South Africa, Malawi and Nepal, are awaited. 
High circulating HIV viral load has been shown to be a risk factor for HIV 
progression (5). It has been suggested that the relationship between vitamin A 
levels and viral load is of potential importance, since in vitro studies suggest that 
vitamin A supplementation may up-regulate the expression of HIV (6). However, a 
recent randomized controlled trial of high dose supplementation in HIV-infected 
adults showed that vitamin A supplementation had no effect on viral load (7). This 
would suggest that vitamin A deficiency and viral load are independent risk factors 
for the progression of HIV disease. 
In Sub-Saharan Africa where antiretroviral therapies are prohibitively expensive, the 
optimization of micronutrient status may be among the affordable strategies 
available for potentially prolonging survival in HIV disease and reducing vertical 
transmission of HIV. Vitamin A or ~-carotene supplementation may prove to be an 
effective low cost intervention strategy to improve the morbidity and mortality of 
HIV-infected adults and children. 
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Staging System for HIV Infection and 
' Appendices 
I. Definitions and diagnostic criteria for the clinical 
conditions listed in Table 1 
These consensus . crire=ia were esublished during 
:i. Consult.Jtion convened by WHO;GPA during che 
\ U [ncernational Coderence on AIDS (Florence, 
June 1991), ~ith the foUowing participancs: P. Cahn 
(Argentina); B. Tindall (Australia); R. Colebunders 
(Belgium); M. Schechcer (Brazil); J.S.G. ~!oncaner 
( C:in::ida); A. L:lz.z::irin (Italy); R. Coutinho, R. Keec (The 
~~~cherlands): J. Gonz:ilez-Llhoz. (Sp:iin); R. ~luge~-a , 
l Cg:mda); J. Curran, A. Sa.ah (USA); 8. Kapita (b..ire); 
D. H~mann, M. Kar::un, P. Cracchiolo (WHO). 
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Persistent generalized l~mphadenop:.ithy: palpable 
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.\cute retro\·iral infe:j on: unexrl::uned :1.crne febrile 
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l nincentional weight !ass: percenc:ige of cot.J.! body 
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a ch~·. continuously or episodic:tlly. for more dun 1 
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.m.nc for more than 1 month (if self-reported, docu-
mented ac leisc once). 
Or:u c:i.ndidiisis: e~,~.ne:natous: red area "'ithouc re-
mo\·::i.ble pl:iques, often on palate, dorsum of the 
tongue md bucc:tl mucosa: pseudomembranous: 
n·hice or yellow removable plaques mywhere in the 
or:u C:J.\ity. 
Or:u hai~· leukoplaka: -:vhice, non-removd,ble lesions, 
usu:tlJ\· bilacer.tlly en the margins of the tongue. The 
surface is corrug:i.ted. but could be non-corrug;iced if 
on the inferior surface of the tongue. 
Pulmonary rubercuiosis: C\-pical: disease c:1used by 
:icid -f:t.sc mycobac:e::1a. invohing the lungs ( includ-
ing pleucitis a.nd p:1cidar l~rnph:i.denitis ) , presencing 
~ich Jpic:tl c:i."itation J.nd/or pleur:tl effusion: arypic:tl: 
JS :i.bove. but prese:i ting <:>.i chout :1pic:i..l c:r.;C;J.tio n and 
pleur:i.l effus ion. 
APPEND\Xl 
:uESTIONNAIRE: VITAMIN A STUDY 
RECORD NUMBER: GSH ...... . 
DATE: .... / .... /1996 
1. PATIENT NAME: ........... . 
FOLDER NUMBER: ........... . 
2. Gender: 
II Male Female 2 )I 
3. Age at present: 
II ii 
4. Address: 
SOCIO-ECONOMIC DATA: TO BE COMPLETED FOR ALL PATIENTS 
5. What type of house do you live in? 
Ii ?ormal house 
I I Informal housing ~I 
6. How many rooms are there (excluding toilets and bathrooms) 
in the house/ place that you live? 
ICJI rooms 
11 
7. How many people ( including children) sleep in the house 
most of the week? 
IL II people 11 
8. Do you have electricity in the house? 
11 
Yes ' I No '2. j Don't know 
9. Is there a working fridge in your house ? 
Ii Yes No 21 _ Don't know 
10. Did you attend school? 
IF YES, GO TO 11. 
IF NO, GO TO 12. 
11 
Yes No 
11. What is highest standard that you passed? 





RECORD NUMBER GSn ....... . 
12. Do you work :or money or goods at present? 
IF YES, GO TO 13. 
IF NO, GO TO 14. 
II Yes No 
13. What type c: work do you do for money or goods? 
Please spec:.:y ................................ . 
14.1 If you not ~orking are you? 
Unemployed 1 D' '·1· '2-lSaOl ity Student ~ Homemaker4- Other 
gra::it 
5 
If other, please specify ................................... . 
14.2 How long ha7e you not been working? 
II I months II 
15. Do you drin.:-<:: alcohol at present ? 
II Yes No 
'2. 
II 
IF NO, GO ,,..,,.... 16. -~ 
IF YES, GO -:''.) 17. 
16.1 Have you ever drunk alcohol in the past ? 
II Yes 
._ I No 2
11 
16.2 How long ag::::: did you stop drinking alcohol ? 
months II 
ANTHROPOMETRIC DATA: TO BE COMPLETED FOR ALL PATIENTS 
17. Weight: 
II I , kg II 
18. Height: 
II cm 11 
19. Body Mass :::::cdex (BMI) 
II I , kg/m2 11 
CLINICAL DATA:~,.... BE COMPLETED FOR ALL PATIENTS 
20. Time since ~=v diagnosis: 
II months 
21. Temperature: 
I , C II 
APPEND\X l1f -
l The SAS System 4 
15:07 Tuesday, September 8, 1998 
The LOGISTIC Procedure 
Data Set: WORK.DATAl 
Response Variable: STAGE4 
Response Levels: 2 
Number of Observations: 125 
Link Function: Logit 
Response Profile 
Ordered 





























Chi-Square for Covariates 
21.985 with 5 DF (p=0.0005) 
20.543 with 5 DF (p=0.0010) 
Analysis of Maximum Likelihood Estimates 
Parameter Standard Wald Pr > Standardized Odds 
Estimate Error Chi-Square Chi-Square Estimate Ratio 
-5.0370 2.0456 6.0628 0. 0138 
1.2056 0.5109 5.5684 0.0183 0.333404 3.339 
0.9242 0.4705 3.8592 0.0495 0.254801 2. 520 
0.3733 0.4796 0.6058 0.4364 0.103238 1. 453 
-0.0119 0.0183 0.4184 0.5178 -0.105558 0.988 
0.5548 0.4778 1.3486 0.2455 0.142293 1.742 
Association of Predicted Probabilities and Observed Responses 
Concordant 77.0% Somers' D 0.542 
Discordant 22. n Gamma 0.544 
Tied 0.3* Tau-a 0.208 
( 2 976 pairs) C 0.771 
l The SAS System 4 
15:08 Tuesday, September 8, 1998 
The LOGISTIC Procedure 
Data Set: WORK.DATAl 
Response Variable: STAGE4 
Response Levels: 2 
Number of Observations: 125 
Link Function: Logit 
Response Profile 
Ordered 





























Chi-Square for Covariates 
25.748 with 5 DF (p=0.0001) 
25.464 with 5 DF (p=0.0001) 
Analysis of Maximum Likelihood Estimates 
Parameter Standard Wald Pr> Standardized Odds 
Estimate Error Chi-Square Chi-Square Estimate Ratio 
-5.1798 2.0340 6.4853 0.0109 
1. 0684 0.5246 4.1473 0.0417 0.295471 2. 911 
1. 3702 0.4947 7. 6721 0.0056 0.346223 3.936 
0.4250 0.4894 0.7539 0.3852 0.117521 1. 530 
-0.00886 0.0186 0.2257 0.6347 -0.078821 0.991 
0.2893 0. 5071 0.3255 0.5683 0.074196 1. 335 
Association of Predicted Probabilities and Observed Responses 
Concordant 77.4% Somers' D 0.553 
Discordant 22 .1% Gamma 0.556 
Tied 0.5% Tau-a 0.212 
( 2976 pairs) C 0.776 
l The SAS System 1 
15:09 Tuesday, September 8, 1998 
The LOGISTIC Procedure 
Data Set: WORK.DATAl 
Response Variable: RET30 
Response Levels: 2 
Number of Observations: 126 
Link Function: Logit 
Response Profile 
Ordered 






























Chi-Square for Covariates 
25.188 with 4 DF (p=0.0001) 
22.780 with 4 DF (p=0.0001) 
Analysis of Maximum Likelihood Estimates 
Parameter Standard Wald Pr> Standardized Odds 
Estimate Error Chi-Square Chi-Square Estimate Ratio 
-0.1116 1.3385 0.0069 0.9336 
0.3053 0.4122 0.5487 0.4589 0.084121 1. 357 
1. 2248 0.5062 5.8550 0.0155 0.295108 3.404 
0.8585 0.4013 4.5756 0.0324 0.237328 2.360 
-0.0287 0.0151 3.6101 0.0574 -0.257419 0.972 
Association of Predicted Probabilities and Observed Responses 
Concordant 72. 8% Somers' D 0.460 
Discordant 26.9% Gamma 0.461 
Tied 0.3% Tau-a 0.231 
(3965 pairs) C 0.730 
1 The SAS System 2 
15:09 Tuesday, September 8, 1998 
The LOGISTIC Procedure 
Data Set: WORK.DATAl 
Response Variable: RET30 
Response Levels: 2 
Number of Observations: 126 


































Chi-Square for Covariates 
26.689 with 4 OF (p=0.0001) 
23.893 with 4 OF (p=0.0001) 
Analysis of Maximum Likelihood Estimates 
Parameter Standard Wald Pr> Standardized Odds 
Estimate Error Chi-Square Chi-Square Estimate Ratio 
-0.6476 1.3752 0.2218 0.6377 
0.6813 0.4791 2.0221 0.1550 0.171747 1.976 
1.1102 0.5175 4.6033 0.0319 0.267493 3.035 
0.8733 0.4012 4.7375 0.0295 0.241436 2.395 
-0.0268 0.0151 3.1509 0.0759 -0.240296 0.974 
Association of Predicted Probabilities and Observed Responses 
Concordant 73.H Somers' D 0. 4 67 
Discordant 26.5% Gamma 0.469 
Tied 0.4% Tau-a 0.235 
(3965 pairs) C 0.733 
